Found: 33
Select item for more details and to access through your institution.
Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
- Published in:
- Journal of Cellular Biochemistry, 2010, v. 111, n. 4, p. 782, doi. 10.1002/jcb.22781
- By:
- Publication type:
- Article
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. e77, doi. 10.1093/oncolo/oyac234
- By:
- Publication type:
- Article
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Inflammatory Breast Cancer--The Royal Marsden Hospital Experience.
- Published in:
- Cancer (0008543X), 2010, v. 116, p. 2815, doi. 10.1002/cncr.25178
- By:
- Publication type:
- Article
Inflammatory breast cancer--The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Ipsilateral Breast Tumor Recurrence: Is There Any Evidence for Benefit of Further Systemic Therapy?
- Published in:
- Breast Journal, 2009, v. 15, n. 3, p. 268, doi. 10.1111/j.1524-4741.2009.00716.x
- By:
- Publication type:
- Article
A review on the added value of whole-body MRI in metastatic lobular breast cancer.
- Published in:
- European Radiology, 2022, v. 32, n. 9, p. 6514, doi. 10.1007/s00330-022-08714-6
- By:
- Publication type:
- Article
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00639-1
- By:
- Publication type:
- Article
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00533-2
- By:
- Publication type:
- Article
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00483-1
- By:
- Publication type:
- Article
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
- Published in:
- Drugs, 2019, v. 79, n. 17, p. 1849, doi. 10.1007/s40265-019-01208-8
- By:
- Publication type:
- Article
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231151840
- By:
- Publication type:
- Article
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
- Published in:
- Breast Cancer Research, 2012, v. 14, n. 5, p. 3330, doi. 10.1186/bcr3330
- By:
- Publication type:
- Article
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference.
- Published in:
- Cancer (0008543X), 2008, v. 112, p. 673, doi. 10.1002/cncr.23194
- By:
- Publication type:
- Article
Enhancing endocrine response with novel targeted therapies.
- Published in:
- Cancer (0008543X), 2008, v. 112, p. 710, doi. 10.1002/cncr.23190
- By:
- Publication type:
- Article
Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
- Published in:
- 2008
- By:
- Publication type:
- journal article
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
- Published in:
- 2008
- By:
- Publication type:
- research
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Endocrine therapy – current benefits and limitations.
- Published in:
- Breast Cancer Research & Treatment, 2005, v. 93, n. 0, p. 3, doi. 10.1007/s10549-005-9036-4
- By:
- Publication type:
- Article
Enhancing the Efficacy of Hormonal Agents with Selected Targeted Agents.
- Published in:
- Clinical Breast Cancer, 2009, v. 9, p. S28, doi. 10.3816/CBC.2009.s.003
- By:
- Publication type:
- Article
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.830097
- By:
- Publication type:
- Article
Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Screening for ESR mutations in breast and ovarian cancer patients.
- Published in:
- Human Mutation, 1997, v. 9, n. 6, p. 531, doi. 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4
- By:
- Publication type:
- Article
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic.
- Published in:
- NPJ Breast Cancer, 2020, v. 6, n. 1, p. 1, doi. 10.1038/s41523-020-0168-9
- By:
- Publication type:
- Article
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 6, p. 1139, doi. 10.1007/s00280-009-0975-z
- By:
- Publication type:
- Article
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0157397
- By:
- Publication type:
- Article